<?xml version="1.0" encoding="utf-8"?>
<rss 
  version="2.0">
  <channel xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/">
    <title>iBio, Inc.</title>
    <link>https://www.globenewswire.com/rssfeed/organization/HCx5c2vDCkzMVhPLwLqfjQ==</link>
    <description>Contains the last 20 releases</description>
    <copyright>Copyright 2024, iBio, Inc.</copyright>
    <managingEditor>newsdesk@globenewswire.com (NewsDesk)</managingEditor>
    <lastBuildDate>Tue, 12 Nov 2024 21:05:00 GMT</lastBuildDate>
    <webMaster>webmaster@globenewswire.com (Webmaster)</webMaster>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/11/12/2979659/0/en/iBio-Reports-Fiscal-First-Quarter-2025-Financial-Results.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/11/12/2979659/0/en/iBio-Reports-Fiscal-First-Quarter-2025-Financial-Results.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio Reports Fiscal First Quarter 2025 Financial Results</title>
      <description><![CDATA[Advanced myostatin program with dosing underway in non-human primate study <pre>Advanced myostatin program with dosing underway in non-human primate study</pre>]]></description>
      <pubDate>Tue, 12 Nov 2024 21:05 GMT</pubDate>
      <dc:identifier>2979659</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Tue, 12 Nov 2024 21:05 GMT</dc:modified>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/10/10/2961263/0/en/iBio-and-AstralBio-Provide-Update-on-Myostatin-Program-for-Obesity.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/10/10/2961263/0/en/iBio-and-AstralBio-Provide-Update-on-Myostatin-Program-for-Obesity.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio and AstralBio Provide Update on Myostatin Program for Obesity</title>
      <description><![CDATA[Lead molecule identified with potential extended half-life and subcutaneous dosing <pre>Lead molecule identified with potential extended half-life and subcutaneous dosing</pre>]]></description>
      <pubDate>Thu, 10 Oct 2024 12:00 GMT</pubDate>
      <dc:identifier>2961263</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Thu, 10 Oct 2024 12:00 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/20/2949885/0/en/iBio-Reports-Fiscal-Year-2024-Financial-Results-and-Provides-Corporate-Update.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/09/20/2949885/0/en/iBio-Reports-Fiscal-Year-2024-Financial-Results-and-Provides-Corporate-Update.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update</title>
      <description><![CDATA[<p align="justify">SAN DIEGO, Sept.  20, 2024  (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=8cIrZccEbBmHzRk14U1ikNb0tQzMMFe5aBcKWkFnaV-tEqm7ghUzdnYJlBMsRuObBkLNuBdHMvbbbPVYxQlCOg==" rel="nofollow" target="_blank" title="iBio, Inc.">iBio, Inc.</a> (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and provided a corporate update.<br></p>]]></description>
      <pubDate>Fri, 20 Sep 2024 20:05 GMT</pubDate>
      <dc:identifier>2949885</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Fri, 20 Sep 2024 20:05 GMT</dc:modified>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/09/03/2939497/0/en/iBio-to-Participate-in-Upcoming-Investor-Conferences.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/09/03/2939497/0/en/iBio-to-Participate-in-Upcoming-Investor-Conferences.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio to Participate in Upcoming Investor Conferences</title>
      <description><![CDATA[<p align="justify">SAN DIEGO, Sept.  03, 2024  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin Brenner, DVM, Ph.D., and Chief Financial Officer, Felipe Duran, will participate in upcoming investor conferences.<br></p>]]></description>
      <pubDate>Tue, 03 Sep 2024 11:00 GMT</pubDate>
      <dc:identifier>2939497</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Tue, 03 Sep 2024 11:00 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/08/12/2928796/0/en/iBio-Expands-Executive-Leadership-Team-with-Appointment-of-Kristi-Sarno-as-Senior-Vice-President-of-Business-Development.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/08/12/2928796/0/en/iBio-Expands-Executive-Leadership-Team-with-Appointment-of-Kristi-Sarno-as-Senior-Vice-President-of-Business-Development.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development</title>
      <description><![CDATA[Life sciences industry veteran to lead strategic alliances for iBio’s machine learning platform for antibody discovery and pipeline of cardiometabolic targets <pre>Life sciences industry veteran to lead strategic alliances for iBio’s machine learning platform for antibody discovery and pipeline of cardiometabolic targets</pre>]]></description>
      <pubDate>Mon, 12 Aug 2024 20:30 GMT</pubDate>
      <dc:identifier>2928796</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Mon, 12 Aug 2024 20:30 GMT</dc:modified>
      <dc:subject>Directors and Officers</dc:subject>
      <dc:subject>Changes in share capital and votes</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/06/03/2892093/0/en/iBio-Closes-Sale-of-Manufacturing-Facility-in-Texas.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/06/03/2892093/0/en/iBio-Closes-Sale-of-Manufacturing-Facility-in-Texas.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio Closes Sale of Manufacturing Facility in Texas</title>
      <description><![CDATA[<p align="center"><em>– </em><em>The sale of the facility eliminates $13.2M of secured debt –</em></p>]]></description>
      <pubDate>Mon, 03 Jun 2024 11:00 GMT</pubDate>
      <dc:identifier>2892093</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Mon, 03 Jun 2024 11:00 GMT</dc:modified>
      <dc:subject>Business Contracts</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/05/13/2880862/0/en/iBio-Reports-Fiscal-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/05/13/2880862/0/en/iBio-Reports-Fiscal-Third-Quarter-2024-Financial-Results-and-Provides-Corporate-Update.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update</title>
      <description><![CDATA[<p align="justify">BRYAN, Texas and SAN DIEGO, May  13, 2024  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported financial results for the third quarter ended March 31, 2024 and provided a corporate update.</p>]]></description>
      <pubDate>Mon, 13 May 2024 20:05 GMT</pubDate>
      <dc:identifier>2880862</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Mon, 13 May 2024 20:05 GMT</dc:modified>
      <dc:subject>Earnings Releases and Operating Results</dc:subject>
      <dc:keyword>Earnings</dc:keyword>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/03/27/2853011/0/en/iBio-and-AstralBio-Announce-Transformative-AI-drug-discovery-Collaboration-to-Rapidly-Develop-Novel-Antibodies-for-Obesity-and-Cardiometabolic-Diseases.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/03/27/2853011/0/en/iBio-and-AstralBio-Announce-Transformative-AI-drug-discovery-Collaboration-to-Rapidly-Develop-Novel-Antibodies-for-Obesity-and-Cardiometabolic-Diseases.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases</title>
      <description><![CDATA[<p align="center"><em>– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments –</em><br></p>]]></description>
      <pubDate>Wed, 27 Mar 2024 11:00 GMT</pubDate>
      <dc:identifier>2853011</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Wed, 27 Mar 2024 11:00 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Partnerships</dc:subject>
      <dc:subject>Conference Calls/ Webcasts</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/03/26/2852850/0/en/iBio-Announces-15-0-Million-Private-Placement.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/03/26/2852850/0/en/iBio-Announces-15-0-Million-Private-Placement.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio Announces $15.0 Million Private Placement</title>
      <description><![CDATA[<p align="center"><em>– Purchase price of $2.85 represents a premium of 148+% to last close –</em><br></p>]]></description>
      <pubDate>Tue, 26 Mar 2024 23:35 GMT</pubDate>
      <dc:identifier>2852850</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Tue, 26 Mar 2024 23:35 GMT</dc:modified>
      <dc:subject>Financing Agreements</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/02/26/2835048/0/en/iBio-Announces-Sale-of-Preclinical-PD-1-Agonist-Antibody-Program-to-Otsuka.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/02/26/2835048/0/en/iBio-Announces-Sale-of-Preclinical-PD-1-Agonist-Antibody-Program-to-Otsuka.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka</title>
      <description><![CDATA[<p align="center"><em>– Deal includes $1 million upfront and potential future milestone payments </em>–<br></p>]]></description>
      <pubDate>Mon, 26 Feb 2024 12:45 GMT</pubDate>
      <dc:identifier>2835048</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Mon, 26 Feb 2024 12:45 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Mergers and Acquisitions</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2024/01/16/2809865/0/en/iBio-Announces-Participation-in-23rd-Annual-PepTalk-Conference.html</guid>
      <link>https://www.globenewswire.com/news-release/2024/01/16/2809865/0/en/iBio-Announces-Participation-in-23rd-Annual-PepTalk-Conference.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio Announces Participation in 23rd Annual PepTalk Conference</title>
      <description><![CDATA[- VP of Platform Technologies, Matt Greving, to give podium presentation on enhancing bispecific T-cell engager discovery and development with machine learning - <pre>- VP of Platform Technologies, Matt Greving, to give podium presentation on enhancing bispecific T-cell engager discovery and development with machine learning -</pre>]]></description>
      <pubDate>Tue, 16 Jan 2024 13:15 GMT</pubDate>
      <dc:identifier>2809865</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Tue, 16 Jan 2024 13:15 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Conference Calls/ Webcasts</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/12/26/2801051/0/en/iBio-Amends-and-Extends-Maturity-of-Credit-Agreement.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/12/26/2801051/0/en/iBio-Amends-and-Extends-Maturity-of-Credit-Agreement.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio Amends and Extends Maturity of Credit Agreement</title>
      <description><![CDATA[<p align="center"><em>– Extends maturity date to March 29, 2024 –</em><br></p>]]></description>
      <pubDate>Tue, 26 Dec 2023 12:15 GMT</pubDate>
      <dc:identifier>2801051</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Tue, 26 Dec 2023 12:15 GMT</dc:modified>
      <dc:subject>Financing Agreements</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/12/05/2790859/0/en/iBio-Inc-Announces-Pricing-of-4-5-Million-Public-Offering.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/12/05/2790859/0/en/iBio-Inc-Announces-Pricing-of-4-5-Million-Public-Offering.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio, Inc. Announces Pricing of $4.5 Million Public Offering</title>
      <description><![CDATA[<p align="justify">BRYAN, Texas and SAN DIEGO, Dec.  05, 2023  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), today announced the pricing of its reasonable best efforts public offering of 2,250,000 of its shares of common stock (or common stock equivalents in lieu thereof) and accompanying Series C and Series D warrants to purchase up to an aggregate of 2,250,000 shares of common stock at a combined public offering price of $2.00, resulting in gross proceeds of approximately $4.5 million. The Series C Warrants to purchase up to an aggregate of 2,250,000 shares of common stock and Series D Warrants to purchase up to an aggregate of 2,250,000 shares of common stock will have an exercise price of $2.00 per share, will be exercisable immediately following the date of issuance and will expire two years and five years from the original issuance date, respectively.<br></p>]]></description>
      <pubDate>Tue, 05 Dec 2023 13:00 GMT</pubDate>
      <dc:identifier>2790859</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Tue, 05 Dec 2023 13:01 GMT</dc:modified>
      <dc:subject>Stock Market News</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/11/27/2786548/0/en/iBio-Announces-Reverse-Stock-Split.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/11/27/2786548/0/en/iBio-Announces-Reverse-Stock-Split.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio Announces Reverse Stock Split</title>
      <description><![CDATA[<p align="justify">BRYAN, Texas and SAN DIEGO, Nov.  27, 2023  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”) today announced that its Board of Directors has approved a 20-to-1 reverse split of the Company’s common stock, par value $0.001 per share (the “Common Stock”) effective at 12:01 a.m. ET on November 29, 2023 (the “Effective Date”). The Common Stock is expected to begin trading on a split-adjusted basis when the market opens on November 29, 2023, with the new CUSIP number 451033708.   <br></p>]]></description>
      <pubDate>Mon, 27 Nov 2023 22:20 GMT</pubDate>
      <dc:identifier>2786548</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Mon, 27 Nov 2023 22:20 GMT</dc:modified>
      <dc:subject>Changes in share capital and votes</dc:subject>
      <dc:subject>Changes in company's own shares</dc:subject>
      <dc:subject>Major shareholder announcements</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/11/01/2771164/0/en/iBio-Further-Expands-Tech-Stack-with-ShieldTx-Enhances-Immuno-Oncology-Development-Pipeline-with-Conditionally-Activated-MUC16xCD3-Bispecific.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/11/01/2771164/0/en/iBio-Further-Expands-Tech-Stack-with-ShieldTx-Enhances-Immuno-Oncology-Development-Pipeline-with-Conditionally-Activated-MUC16xCD3-Bispecific.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio Further Expands Tech Stack with ShieldTx™; Enhances Immuno-Oncology Development Pipeline with Conditionally Activated MUC16xCD3 Bispecific</title>
      <description><![CDATA[<p align="center"><em>- ShieldTx potentially increases safety and developability of therapeutic antibodies for difficult targets and modes of action -</em><br></p>]]></description>
      <pubDate>Wed, 01 Nov 2023 12:24 GMT</pubDate>
      <dc:identifier>2771164</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Wed, 01 Nov 2023 12:24 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Product / Services Announcement</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/10/10/2757444/0/en/iBio-to-Highlight-Technology-for-Advancing-Discovery-of-Bispecifics-at-Festival-of-Biologics.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/10/10/2757444/0/en/iBio-to-Highlight-Technology-for-Advancing-Discovery-of-Bispecifics-at-Festival-of-Biologics.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio to Highlight Technology for Advancing Discovery of Bispecifics at Festival of Biologics</title>
      <description><![CDATA[<p align="center"><em>- VP of Platform Technologies, Matt Greving, to present data on enhancing T-cell engagers using machine-learning guided epitope steering and mammalian display antibody libraries -</em><br></p>]]></description>
      <pubDate>Tue, 10 Oct 2023 12:00 GMT</pubDate>
      <dc:identifier>2757444</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Tue, 10 Oct 2023 12:02 GMT</dc:modified>
      <dc:subject>Calendar of Events</dc:subject>
      <dc:subject>Health</dc:subject>
      <dc:subject>Clinical Study</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/10/02/2752591/0/en/iBio-Explains-Recent-Filing-of-Registration-Statement.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/10/02/2752591/0/en/iBio-Explains-Recent-Filing-of-Registration-Statement.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio Explains Recent Filing of Registration Statement</title>
      <description><![CDATA[–  No new securities are being registered under the Post-Effective Amendment – <pre>–  No new securities are being registered under the Post-Effective Amendment –</pre>]]></description>
      <pubDate>Mon, 02 Oct 2023 10:45 GMT</pubDate>
      <dc:identifier>2752591</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Mon, 02 Oct 2023 10:45 GMT</dc:modified>
      <dc:subject>Company Regulatory Filings</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/09/27/2750762/0/en/iBio-Announces-Filing-of-2023-Annual-Report-on-SEC-Form-10-K.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/09/27/2750762/0/en/iBio-Announces-Filing-of-2023-Annual-Report-on-SEC-Form-10-K.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio Announces Filing of 2023 Annual Report on SEC Form 10-K</title>
      <description><![CDATA[<p align="justify">BRYAN, Texas and SAN DIEGO, Sept.  27, 2023  (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, announced today the filing of its annual report on Form 10-K with the United States Securities and Exchange Commission ("SEC") for the fiscal year ended June 30, 2023.<br></p>]]></description>
      <pubDate>Wed, 27 Sep 2023 20:19 GMT</pubDate>
      <dc:identifier>2750762</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Wed, 27 Sep 2023 20:20 GMT</dc:modified>
      <dc:subject>Company Regulatory Filings</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/09/21/2747658/0/en/iBio-Announces-Amendment-to-Credit-Agreement-with-Woodforest.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/09/21/2747658/0/en/iBio-Announces-Amendment-to-Credit-Agreement-with-Woodforest.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio Announces Amendment to Credit Agreement with Woodforest</title>
      <description><![CDATA[<p align="center">– Extends maturity date to December 31, 2023 –</p>]]></description>
      <pubDate>Thu, 21 Sep 2023 20:05 GMT</pubDate>
      <dc:identifier>2747658</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Thu, 21 Sep 2023 22:58 GMT</dc:modified>
      <dc:subject>Financing Agreements</dc:subject>
    </item>
    <item>
      <guid
        isPermaLink="true">https://www.globenewswire.com/news-release/2023/08/14/2725022/0/en/iBio-Reports-Triple-Milestone-In-Vivo-Proof-of-Concept-for-Three-Programs-a-Transformative-Step-in-Advancing-its-Immuno-Oncology-Pre-Clinical-Pipeline-Towards-Clinical-Development.html</guid>
      <link>https://www.globenewswire.com/news-release/2023/08/14/2725022/0/en/iBio-Reports-Triple-Milestone-In-Vivo-Proof-of-Concept-for-Three-Programs-a-Transformative-Step-in-Advancing-its-Immuno-Oncology-Pre-Clinical-Pipeline-Towards-Clinical-Development.html</link>
      <category
        domain="https://www.globenewswire.com/rss/stock">NYSE:IBIO</category>
      <category
        domain="https://www.globenewswire.com/rss/ISIN">US45107K1025</category>
      <title>iBio Reports Triple Milestone: In Vivo Proof-of-Concept for Three Programs, a Transformative Step in Advancing its Immuno-Oncology Pre-Clinical Pipeline Towards Clinical Development</title>
      <description><![CDATA[<p align="center"><em>– </em><em>AI-powered technology enables rapid, simultaneous progress of antibodies against challenging targets </em><em>–</em><br></p>]]></description>
      <pubDate>Mon, 14 Aug 2023 20:15 GMT</pubDate>
      <dc:identifier>2725022</dc:identifier>
      <dc:language>en</dc:language>
      <dc:publisher>GlobeNewswire Inc.</dc:publisher>
      <dc:contributor>iBio, Inc.</dc:contributor>
      <dc:modified>Mon, 14 Aug 2023 20:15 GMT</dc:modified>
      <dc:subject>Health</dc:subject>
      <dc:subject>Product / Services Announcement</dc:subject>
    </item>
  </channel>
</rss>